Looking closely at histological subtypes, for NSCLC, mortality declined from 2006 to 2013, when it underwent an acceleration, shortly after the introduction of routine molecular testing for EGFR and ALK and targeted therapies became available. This evidence concerns the gene EGFR and non-small cell lung carcinoma.